Patents for A61P 35 - Antineoplastic agents (221,099)
04/1999
04/22/1999WO1999019494A1 Human ribonuclease a with reduced ribonuclease inhibitor affinity
04/22/1999WO1999019486A1 Cell division regulators
04/22/1999WO1999019483A1 Human progesterone receptor complex p23-like protein
04/22/1999WO1999019481A2 Mammalian genes involved in viral infection and tumor suppression
04/22/1999WO1999019479A1 Murine model for human carcinoma
04/22/1999WO1999019478A1 Agonist and antagonist peptides of carcinoembryonic antigen (cea)
04/22/1999WO1999019466A2 Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
04/22/1999WO1999019365A1 Novel pectic polysaccharides purified from angelica gigas nakai and purification method and use as immuno-stimulating agent thereof
04/22/1999WO1999019359A1 Cellular receptor for hiv-1 vpr essential for g2/m phase transition of the cell cycle
04/22/1999WO1999019354A1 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
04/22/1999WO1999019346A1 Dipeptides for the treatment of diseases related to the biological effect of endothelin
04/22/1999WO1999019320A1 Novel pharmaceutically active compounds, their preparation and use as ece-inhibitors
04/22/1999WO1999019319A1 Synthetic methods for polyphenols
04/22/1999WO1999019298A1 iso-CBI AND iso-CI ANALOGS OF CC-1065 AND THE DUOCARMYCINS
04/22/1999WO1999019293A1 Novel aryloxy-alkyl-dialkylamines
04/22/1999WO1999018997A1 Potentiator for antibody against lymphoid tumor
04/22/1999WO1999018995A1 Immunogenic peptides from the hpv e7 protein
04/22/1999WO1999018987A1 Ligand binding site of rage and uses thereof
04/22/1999WO1999018981A1 Implants comprising combinations of allogeneic cells for use in cancer treatment
04/22/1999WO1999018951A1 Inhibitors of farnesyl protein transferase
04/22/1999WO1999018799A1 Treatment of neoplasms with viruses
04/22/1999WO1999018798A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
04/22/1999WO1999011624B1 Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
04/22/1999WO1999006387A3 O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents
04/22/1999WO1999006361A3 N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
04/22/1999WO1999004806A9 Methods and compositions for inhibiting angiogenesis
04/22/1999WO1999001118A3 Antioxidant enhancement of therapy for hyperproliferative conditions
04/22/1999WO1998048837A9 Polyalkylene oxide-modified single chain polypeptides
04/22/1999WO1998045328A3 Compositions and methods for the treatment and diagnosis of breast cancer
04/22/1999WO1998044788A9 Animal model for evaluation of vaccines
04/22/1999WO1998044143A9 Polymer-modified viruses
04/22/1999DE19746173A1 Tumor vaccine based on tumor antigens comprises a slow-release system of gamma-interferon (IFN-gamma
04/22/1999CA2792406A1 Methods for encapsulating nucleic acids in lipid bilayers
04/22/1999CA2696653A1 Mammalian genes involved in viral infection and tumor suppression
04/22/1999CA2307328A1 Cell division regulators
04/22/1999CA2307208A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
04/22/1999CA2306851A1 Synthetic methods for polyphenols
04/22/1999CA2306453A1 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
04/22/1999CA2306443A1 Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
04/22/1999CA2306440A1 Cellular receptor for hiv-1 vpr essential for g2/m phase transition of the cell cycle
04/22/1999CA2306420A1 Iso-cbi and iso-ci analogs of cc-1065 and the duocarmycins
04/22/1999CA2305698A1 Human progesterone receptor complex p23-like protein
04/22/1999CA2305643A1 Murine model for human carcinoma
04/22/1999CA2305499A1 Novel pharmaceutically active compounds, their preparation and use as ece-inhibitors
04/22/1999CA2304473A1 Inhibitors of farnesyl protein transferase
04/21/1999EP0909763A2 Colchicine derivatives and the therapeutical use thereof
04/21/1999EP0909560A2 Treatment o tumors with compounds having RXR retinoid receptor agoinst activity
04/21/1999EP0909277A2 Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
04/21/1999EP0909271A1 Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation
04/21/1999EP0909184A2 Targeted drug delivery using sulfonamide derivatives
04/21/1999EP0909183A2 Dha-pharmaceutical agent conjugates
04/21/1999EP0909182A2 Method for producing chlorins and bacteriochlorins containing polyether
04/21/1999EP0909177A1 Aqueous formulations of peptides
04/21/1999EP0909175A1 Non-aqueous protic peptide formulations
04/21/1999EP0793641B1 Metalloproteinase inhibitors
04/21/1999EP0644947B1 Anti-idiotypic monoclonal antibodies against the lewis y-specific monoclonal antibody br55-2 and their uses
04/21/1999EP0640131B1 Genetically engineered antibodies
04/21/1999EP0369000B1 Macrocyclic complexes of yttrium, the lanthanides and the actinides having peripheral coupling functionalities
04/21/1999CN1214695A ErdB3 antibodies
04/21/1999CN1214694A Peptides with antiproliferative properties
04/21/1999CN1214685A Inhibitors of farnesyl protein transferase
04/21/1999CN1214675A Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids having retinoid-like biological activity
04/21/1999CN1214629A Solid instant-release forms of administration and process for producing the same
04/21/1999CN1214624A Improved tissue destruction in cryosurgery by use of thermal hysteresis proteins
04/21/1999CN1214348A Bivalent reaction water-soluble high molecular derivative and complex including the same
04/20/1999US5895784 Treatment with antimetastasis and antitumor agents
04/20/1999US5895748 Immunoassay of paraffin-embedded biopsies; detection of specific cadherins, catenins, and plaque proteins enables accurate diagnosis of cancer and tumors
04/20/1999US5895648 Two species of bacteria, oligosaccharides dispersed in ingestible natural product
04/15/1999WO1999018235A1 Process for detecting, extracting or removing human or mammalian cells with a disturbed cellular cycle regulation or unlimited proliferation or tumour-forming ability
04/15/1999WO1999018210A2 Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
04/15/1999WO1999018208A1 101 human secreted proteins
04/15/1999WO1999018195A2 Methods and compositions for inducing tumor-specific cytotoxicity
04/15/1999WO1999018191A1 Transgenic animals with knocked-in vec receptor genes and uses thereof
04/15/1999WO1999018142A1 BIODEGRADABLE LOW MOLECULAR WEIGHT TRIBLOCK POLY(LACTIDE-co-GLYCOLIDE) POLYETHYLENE GLYCOL COPOLYMERS HAVING REVERSE THERMAL GELATION PROPERTIES
04/15/1999WO1999018101A1 Benzothiophenes
04/15/1999WO1999018096A1 Inhibitors of prenyl-protein transferase
04/15/1999WO1999018076A1 The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
04/15/1999WO1999018074A1 Novel lactam metalloprotease inhibitors
04/15/1999WO1999018070A1 Novel vitamin d analogues
04/15/1999WO1999018068A1 Styryl sulfone anticancer agents
04/15/1999WO1999017804A1 Polymeric derivatives of camptothecins
04/15/1999WO1999017798A1 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
04/15/1999WO1999017797A1 Use of growth differenciation factor-9 (gdf-9) as a contraceptive
04/15/1999WO1999017796A2 Modulation of lerk-2-mediated cell adhesion
04/15/1999WO1999017787A2 Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
04/15/1999WO1999017778A1 α-KETOAMIDE MULTICATALYTIC PROTEASE INHIBITORS
04/15/1999WO1999017777A1 Inhibitors of prenyl-protein transferase
04/15/1999WO1999017775A1 QUINOLINE-CONTAINING α-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS
04/15/1999WO1999017770A1 Indeno[1,2-c]pyrazole derivatives for inhibiting tyrosine kinase activity
04/15/1999WO1999017769A1 INDENO[1,2-c]-, NAPHTHO[1,2-c]- AND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLE DERIVATIVES
04/15/1999WO1999017764A1 Medicament containing delta-aminolevulinic acid
04/15/1999WO1999017759A2 Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds
04/15/1999WO1999017742A2 Taste masked formulations
04/15/1999WO1999008668A3 Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
04/15/1999WO1999008666A3 Pharmaceutical composition comprising an azateroid
04/15/1999WO1999007324A3 Conjugates targeted to the interleukin-2 receptor
04/15/1999WO1999005170A8 NOVEL ESTROGEN β RECEPTOR AND ISOFORMS
04/15/1999WO1999005103A3 2o(s)-7-ethyl-9-(n-methyl-n-phenyl)amidino-camptothecin, its preparation and its use as antitumor agent
04/15/1999WO1999004821A3 Immobilization of vitamin a acid by cationic polyelectrolytes
04/15/1999WO1999000399A9 Method of producing tiazofurin and other c-nucleosides